Related Experiment Videos
[Interstitial lung disease in a patient given gemcitabine]
V Hammerer1, N Schmitz, G Pauli
1Service de Pneumologie, Hôpital Lyautey, Hôpitaux Universitaires de Strasbourg, 1, rue des Canonniers, 67100 Strasbourg.
Revue De Pneumologie Clinique
|May 1, 2002
Summary
Gemcitabine, a chemotherapy for advanced non-small-cell lung cancer, can cause diffuse interstitial lung disease. Distinguishing this drug-induced lung disease from tumor progression is crucial for patient management.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Distinguishing infectious complications from tumor progression is challenging in patients receiving cytotoxic chemotherapy.
- Gemcitabine is a nucleoside analog commonly used for advanced non-small-cell lung cancer (NSCLC).
Observation:
- A case of diffuse interstitial lung disease (ILD) was observed in a patient undergoing treatment for advanced-stage NSCLC.
- The patient was receiving gemcitabine as part of their cancer therapy.
Findings:
- The observed diffuse interstitial lung disease was determined to be induced by gemcitabine.
- This highlights a potential adverse effect of gemcitabine therapy.
Implications:
- Gemcitabine-induced lung disease necessitates careful monitoring and differential diagnosis in NSCLC patients.
- Early identification of drug-induced lung injury is critical for appropriate treatment adjustments and improved patient outcomes.